NewAmsterdam Pharma (NAMS) Expected to Announce Quarterly Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMS) is projected to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect NewAmsterdam Pharma to post earnings of ($0.48) per share for the quarter.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $20.04 on Wednesday. The business has a fifty day simple moving average of $23.55 and a 200-day simple moving average of $20.18. NewAmsterdam Pharma has a fifty-two week low of $15.19 and a fifty-two week high of $27.29.

Wall Street Analyst Weigh In

NAMS has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Needham & Company LLC reissued a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Scotiabank lifted their price target on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, December 11th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $41.60.

Insider Transactions at NewAmsterdam Pharma

In other news, major shareholder Nap B.V. Forgrowth sold 100,728 shares of the stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $26.10, for a total value of $2,629,000.80. Following the completion of the sale, the insider now owns 10,908,502 shares in the company, valued at $284,711,902.20. This represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 404,927 shares of company stock valued at $10,390,787 over the last ninety days. Corporate insiders own 19.50% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.